Kura Oncology Darlifarnib+Adagrasib Hits 67% Pancreatic, 50% Lung, 29% Colorectal Response Rates
KURA•Kura Oncology’s darlifarnib and adagrasib combination showed 67% objective response in pancreatic cancer, 50% in non-small cell lung cancer and 29% in KRAS inhibitor-naïve colorectal cancer in preliminary Phase 1a data. The company will initiate a platform study of darlifarnib combinations, starting with daraxonrasib in PDAC Phase 1a in 2027.
1. Phase 1a Clinical Data
Preliminary Phase 1a results from darlifarnib combined with adagrasib showed confirmed objective response rates of 67% in pancreatic ductal adenocarcinoma, 50% in non-small cell lung cancer and 29% in KRAS inhibitor–naïve colorectal cancer among 26 response-evaluable patients, including activity in KRAS inhibitor-pretreated subsets.
2. Preclinical Support and Platform Strategy
Translational studies demonstrated that darlifarnib inhibits RHEB farnesylation, sustains mTORC1 suppression and enhances anti-tumor activity across mutant-selective, pan-KRAS and pan-RAS inhibitors; Kura’s planned platform study will assess darlifarnib with multiple targeted agents to optimize combination opportunities.
3. Planned Combinations and Timeline
The first platform arm will evaluate darlifarnib plus daraxonrasib in second-line KRAS-mutant pancreatic cancer, expected to enter Phase 1a in 2027, and the company will host a virtual investor event on June 3 to present data and outline development plans.
